Investigational Theranostic Clinical Trials List
| Diagnostic radiopharmaceutical | Therapeutic radiopharmaceutical and clinical trial name | Sponsor | Indication | Clinicaltrials.gov identifier |
|---|---|---|---|---|
| 68Ga-DOTATATE | 177Lu-DOTATATE (NETTER-2) | Novartis Pharmaceuticals | Somatostatin tumors | NCT03972488 |
| 68Ga-DOTATATE or 64Cu-DOTATATE | 225Ac-RYZ101 (ACTION-1) | RayzeBio | Somatostatin tumors | NCT05477576 |
| 68Ga-DOTATATE | 177Lu-edotreotide (COMPOSE) | ITM Solucin GmbH | Somatostatin tumors | NCT04919226 |
| 64Cu-sartate | 67Cu-sartate | Clarity Pharmaceuticals Ltd. | Neuroblastoma | NCT04023331 |
| 68Ga-PSMA-11 | 177Lu-PSMA-617 (PSMAfore) | Novartis Pharmaceuticals | Prostate cancer | NCT04689828 |
| 68Ga-PSMA-11 | 177Lu-PSMA-617 (PSMAddition) | Novartis Pharmaceuticals | Prostate cancer | NCT04720157 |
| PSMA agent | 177Lu-PSMA-I&T (ECLIPSE) | Curium US LLC | Prostate cancer | NCT05204927 |
| 68Ga-PSMA-11 | 177Lu-DOTA-rosopatamab (PROSTACT) | Telix International Pty Ltd. | Prostate cancer | NCT04876651 |
| PSMA agent | 177Lu-rhPSMA-10.1 | Blue Earth Therapeutics Ltd. | Prostate cancer | NCT05413850 |
| 68Ga-PSMA-11 | 225Ac-PSMA-617 | Telix International Pty Ltd. | Prostate cancer | NCT04597411 |
| 64Cu-SAR-BBN | 67Cu-SAR-BBN (COMBAT) | Clarity Pharmaceuticals Ltd. | Prostate cancer | NCT05633160 |
| 68Ga-NeoB | 177Lu-NeoB (NeoRay) | Advanced Accelerator Applications | Solid tumors | NCT03872778 |
| 68Ga-DOTATATE | 177Lu-DOTATATE | Novartis Pharmaceuticals | Glioblastoma | NCT05109728 |
| 68Ga-FAP-2286 | 177Lu-FAP-2286 (LuMIERE) | Novartis Pharmaceuticals | Solid tumors | NCT04939610 |
| 68Ga-DOTA-FAPI | 177Lu-DOTA-FAPI | First Affiliated Hospital of Xiamen University | Various cancers | NCT04849247 |
| 89Zr-girentuximab | 177Lu-girentuximab | Memorial Sloan Kettering Cancer Center | Renal cancer | NCT05239533 |
| 111In-FPI-1547 | 225Ac-FPI-1434 | Fusion Pharmaceuticals Inc. | Solid tumors | NCT03746431 |